MBX

49.5507.23%
JW

John W. Smither

Independent Director

Mr. John W. Smither, CPA., is Independent Director of Attovia Therapeutics, Inc. from July 02, 2026. Mr. Smither is Chief Financial Officer of MBX Biosciences, Inc. from July 13, 2026. He was Interim Chief Financial Officer of MBX Biosciences, Inc. from March 16, 2026 to July 13, 2026. He is Independent Director of Genelux Corporation from September 11, 2023. He is Independent Director of NewAmsterdam Pharma Company N.V. from January 2023. He is Senior Advisor of Frazier Life Sciences Management, LP from November 2024. He is Senior Advisor of Frazier Management, L.L.C. from November 2024. He joined the Frazier Management, L.L.C. in 2024. He was Director of Principia Biopharma Inc. from February 12, 2019 to May 10, 2019. He was employed at Principia Biopharma Inc. from February 12, 2019 to May 10, 2019. He was Independent Director of Achaogen, Inc. from December 2013. He joined the Achaogen, Inc. in December 2013. He was Chief Financial Officer of Kythera Biopharmaceuticals, Inc. He joined the Kythera Biopharmaceuticals, Inc. in November 2007. He was Independent Director of eFFECTOR Therapeutics, Inc. from August 2021 to September 11, 2023. He was Independent Director of Applied Molecular Transport Inc. from January 27, 2022 to December 2023. He was Chief Financial Officer of Sienna Biopharmaceuticals, Inc. from March 29, 2018 to April 01, 2019. He was employed at Sienna Biopharmaceuticals, Inc. until April 01, 2019. He was Chief Financial Officer of Arcutis Biotherapeutics, Inc. until April 10, 2024. He was CFO & Principal Accounting Officer of Arcutis Biotherapeutics, Inc. He was Interim CFO & Principal Accounting Officer of Arcutis Biotherapeutics, Inc. from August 31, 2023. He was Chief Financial Officer of Arcutis Biotherapeutics, Inc. from May 2019 to March 31, 2021. He was employed at Arcutis Biotherapeutics, Inc. until April 30, 2024. He has B.S. in Business Administration & Accounting from California State University, Los Angeles. Mr. Smither previously served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc. He has experience in finance and accounting in the biotechnology industry. Mr. Smither also has many years’ experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP.

Positions